Skip to content
Concord Biotech logo

Concord Biotech

CONCORDBIO NSE
₹548.20 −8.20 (−1.47%)
Market Cap
₹11,470 Cr
P/E
38.93
View as Markdown
MCP
Close 20 Nov 2026 ₹548.20 1Y −157.65 −22.3%
Start ₹705.85

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
17.40%
Debt to Equity
0.00
EPS (TTM)
₹14.08
Book Value
₹99.70
Market Cap
₹11,470 Cr
P/E (TTM)
38.93
P/B
5.50
ROE
13.00%
Dividend Yield
1.36%
EBITDA
₹420 Cr
52W High
₹807.50
52W Low
₹493.50
Day Range
₹546.10 – ₹558.00
Volume
1,28,839

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Concord Biotech peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Concord Biotech (this company)
548.2038.9311,4705.501.35%13.00%17.40%1,177295
Median 8 companies1,649.9541.351,21,8405.290.70%16.25%17.60%22,7702,808

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
68
Strong
Returns, margins, earnings quality 22% weight
Valuation
53
Average
Cheap vs sector & own history 24% weight
Growth
24
Poor
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
24
Poor
Trend strength, vol-adjusted 12% weight
Ownership
53
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.2%

Weaknesses

2
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has high debtors of 159 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1243
OscillatorsBullish243
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
34.12
Neutral
MACD (12,26,9)
−29.91
Bearish
SMA (50)
664.43
Bearish
SMA (200)
630.83
Bearish

As of

Analyst Rating

Based on 3 analysts
BUY67%

2 of 3 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
2
67%
HOLD
1
33%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+14.35%
5Y+11.33%
3Y+7.34%
1Y−12.08%
TTM+4.62%

Net profit

Net profit growth by window
10Y+11.70%
5Y+2.28%
3Y+3.39%
1Y−29.49%
TTM−8.39%

Operating cash flow

Operating cash flow growth by window
10Y—
5Y+9.59%
3Y+2.38%
1Y+7.76%
TTM—

10Y: The statements do not go back far enough for this window.

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−11.73 pp
5Y−17.43 pp
3Y−4.60 pp
1Y−6.52 pp
TTM−3.34 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹276 Cr
Mar 2018₹340 Cr
Mar 2019₹436 Cr
Mar 2020₹512 Cr
Mar 2021₹617 Cr
Mar 2022₹713 Cr
Mar 2023₹853 Cr
Mar 2024₹1,017 Cr
Mar 2025₹1,200 Cr
Mar 2026₹1,055 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016₹87.00 Cr
Mar 2018₹100 Cr
Mar 2019₹118 Cr
Mar 2020₹169 Cr
Mar 2021₹235 Cr
Mar 2022₹179 Cr
Mar 2023₹238 Cr
Mar 2024₹305 Cr
Mar 2025₹373 Cr
Mar 2026₹263 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹470 Cr +12.0% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Concord Biotech Ltd trades at ₹655.5 as of 2026-11-04 with a market cap of ₹12,834 crore and a PE of 24.33x. The company is virtually debt-free (debt-to-equity of 0) and has a long-term sales CAGR of 14% over 10 years, but recent performance shows a TTM sales decline of 6% and a TTM profit decline of 20%, placing the stock 19% below its 52-week high of ₹807.5.

Bull Case 8
  • The company is essentially debt-free with a debt-to-equity ratio of 0, providing significant financial flexibility and resilience against interest rate cycles.
  • 10-year compounded sales growth of 14% demonstrates a sustained long-term revenue expansion track record in the API and fermentation-based pharma segment.
  • 10-year compounded profit growth of 11% indicates the company has been able to translate top-line growth into earnings over the long term.
  • Healthy dividend payout ratio of 28.2% with a current dividend yield of 1.23% signals management's commitment to returning cash to shareholders despite being a growth-stage specialty pharma company.
  • Return on equity averaged 18% over both 3-year and 5-year periods, reflecting efficient capital deployment relative to the zero-debt balance sheet.
  • ROCE of 16.7% as of 2026-11-04 remains healthy for a healthcare company, suggesting the business generates reasonable returns on total capital employed.
  • Price-to-book ratio of 3.3x is moderate for a debt-free specialty pharma company, and the stock trades 19% below its 52-week high of ₹807.5, which may reflect some correction from elevated levels.
  • 5-year compounded sales growth of 11% outpaces the 3-year sales CAGR of 7%, suggesting the business scaled meaningfully over a broader horizon even if recent growth has moderated.
Bear Case 8
  • TTM profit has declined 20%, a sharp reversal from the 10-year compounded profit growth of 11%, raising concerns about near-term earnings trajectory.
  • TTM sales declined 6%, marking a contraction after years of positive growth and suggesting potential demand softness or pricing pressure in key segments.
  • 3-year and 5-year compounded profit growth are both just 1%, indicating earnings have essentially stagnated over the medium term despite top-line expansion.
  • Debtor days stand at 159, which is notably high and ties up significant working capital, increasing the risk of cash flow strain and potential bad debts.
  • Last year's ROE of 13% has declined from the 3-year and 5-year average of 18%, suggesting deteriorating profitability and less efficient use of equity capital.
  • The stock has delivered a 1-year price CAGR of -17%, underperforming broader indices and reflecting market scepticism about near-term fundamentals.
  • 5-year sales CAGR of 11.3% is considered poor for a specialty pharma company in a high-growth market like India, potentially indicating competitive or structural limitations to scaling.
  • PE of 24.33x on declining TTM earnings means the valuation may not fully reflect the recent downturn in profitability, as the earnings base itself is shrinking.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

14d ago

TL;DR: Concord Biotech successfully completed a 1:1 bonus share allotment, doubling its paid-up capital, which signals management confidence. However, the stock has been under pressure with a 14.28% decline over the past year and trading well below its 52-week high. The bonus issue and strong long-term returns from listing provide support, but near-term momentum remains weak. Investors should watch whether post-bonus trading stabilises or the downtrend continues.

Headwinds 2
  • Stock down 14% over past year Nov 01

    Concord Biotech shares have fallen 14.28% over the past year, with a 9.33% drop in one month and 6.97% decline in two weeks, indicating sustained selling pressure.

  • Well below 52-week high Nov 01

    Stock trading at ₹1,245.30, roughly 23% below its 52-week high of ₹1,614.05 hit on August 20, 2026.

Positives 3
  • 1:1 bonus issue completed Nov 05

    Concord Biotech allotted 10,46,16,204 bonus equity shares in a 1:1 ratio with record date November 4, doubling paid-up share capital to ₹20,92,32,408.

  • 68% gains since listing Nov 01

    Despite recent declines, stock remains up nearly 68% from its IPO issue price of ₹741 per share since its August 2023 listing.

  • Pharma sector bullish sentiment Nov 01

    Shares closed 1.25% higher at ₹1,245.30 amid overall bullish sentiment across pharmaceutical sector stocks during the week.

Neutral 2
  • Nov 4 bonus issue record date Nov 01

    November 4 was set as the record date for the 1:1 bonus issue; investors needed to hold shares by November 3 to qualify.

  • Market cap at ₹13,028 crore Nov 01

    Concord Biotech maintains a market capitalisation of ₹13,027.86 crore with its 52-week low at ₹987.05 on April 2, 2026.

Quarterly Results

₹ Cr
CONCORDBIO quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
262
241
319
216
310
244
430
204
247
278
326
261
312
Expenses
143
135
185
135
174
146
239
143
157
176
204
173
202
Operating Profit
119
106
134
81
137
98
190
61
91
102
122
87
110
OPM %
45%
44%
42%
38%
44%
40%
44%
30%
37%
37%
38%
33%
35%
Other Income
8
8
11
10
10
15
9
14
13
7
16
13
10
Interest
1
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
13
14
14
13
13
13
15
18
18
19
19
18
18
PBT
113
100
131
78
133
99
185
57
86
90
118
82
102
Tax %
25%
26%
26%
25%
26%
25%
23%
26%
26%
25%
24%
26%
26%
Net Profit
84
75
97
58
99
74
142
43
63
68
90
61
76
EPS (₹)
4.04
3.56
4.65
2.78
4.72
3.54
6.78
2.03
3.01
3.24
4.30
2.92
3.62
YoY Sales growth
65
0
17
11
18
1
35
−5
−20
14
−24
28
26

Profit & Loss

₹ Cr
CONCORDBIO profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
239
276
340
436
512
617
713
853
1,017
1,200
1,055
1,177
Expenses
133
145
212
256
308
289
439
509
585
693
678
755
Operating Profit
105
131
127
180
205
328
274
344
432
507
377
422
OPM %
44%
48%
37%
41%
40%
53%
38%
40%
42%
42%
36%
36%
Other Income
11
8
36
17
31
14
23
35
34
44
49
46
Interest
1
0
1
1
1
1
6
5
3
1
1
0
Depreciation
10
10
18
19
21
28
50
54
54
54
74
75
PBT
106
129
144
178
213
313
241
320
409
496
351
393
Tax %
34%
33%
30%
33%
21%
25%
26%
26%
26%
25%
25%
—
Net Profit
70
87
100
118
169
235
179
238
305
373
263
295
EPS (₹)
3.36
4.17
4.80
5.66
8.08
11.25
8.54
11.38
14.57
17.83
12.58
14.08
Div. Payout %
22%
25%
0%
21%
22%
0%
3%
30%
30%
25%
30%
—
Sales growth
—
16
—
28
18
20
16
20
19
18
−12
5

Balance Sheet

₹ Cr
CONCORDBIO balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
9
9
10
10
10
10
10
10
10
10
10
10
Reserves
268
329
585
673
761
990
1,098
1,282
1,515
1,802
2,009
2,076
Borrowings
35
36
22
9
52
89
62
32
10
3
1
1
Other Liabilities
55
74
69
71
118
94
144
191
164
219
216
252
Total Liabilities
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
2,339
Fixed Assets
104
110
189
230
240
546
573
593
575
795
786
764
CWIP
19
70
3
19
141
18
74
173
211
51
79
112
Investments
42
43
151
229
199
142
74
138
244
335
488
535
Other Assets
202
225
343
285
361
477
592
611
668
854
883
928
Total Assets
367
448
685
763
941
1,183
1,313
1,515
1,699
2,034
2,237
2,339

Cash Flow

₹ Cr
CONCORDBIO cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
79
—
155
167
207
246
265
245
264
Investing
—
—
−42
—
−114
−195
−112
−158
−155
−160
−142
Financing
—
—
−37
—
−43
31
−100
−85
−99
−99
−115
Net Cash Flow
—
—
0
—
−1
3
−4
3
12
−14
7
Free Cash Flow
—
—
79
—
−1
−37
52
101
180
134
169
CFO/EBITDA
—
—
101
—
100
74
98
92
85
70
96

Ratios

CONCORDBIO financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
165
182
236
133
131
105
119
117
125
159
159
Inventory Days
276
321
381
310
312
503
434
430
331
286
483
Days Payable
108
129
210
112
201
152
185
190
150
135
150
Cash Conversion Cycle
334
374
407
331
242
456
368
357
306
310
492
Working Capital Days
195
209
275
177
159
177
163
153
166
193
231
ROCE %
—
37%
—
25%
25%
32%
21%
26%
28%
28%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Concord Biotech insights

65 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 44.09%
  • Others 28.87%
  • DIIs 10.95%
  • Public 8.81%
  • FIIs 7.28%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Concord Biotech

What does Concord Biotech Ltd do?
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Where is Concord Biotech Ltd (CONCORDBIO) listed?
Concord Biotech Ltd trades as CONCORDBIO on the NSE and under code 543960 on the BSE.
Which sector does Concord Biotech Ltd belong to?
Concord Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Concord Biotech Ltd?
Concord Biotech Ltd has a market capitalisation of ₹11,470 Cr as of 20 Nov 2026, which places it in the Microcap band.
What is the PE ratio of Concord Biotech Ltd?
Concord Biotech Ltd trades at a PE ratio of 38.93 as of 20 Nov 2026, on earnings per share of ₹14.08, against a book value of ₹99.7 per share.
What is the 52-week high and low of Concord Biotech Ltd?
Over the last 52 weeks Concord Biotech Ltd has traded between ₹493.5 and ₹807.5 as of 20 Nov 2026.
Does Concord Biotech Ltd pay dividends?
Concord Biotech Ltd has a dividend yield of 1.36%.
What is the Return on Equity (ROE) of Concord Biotech Ltd?
Concord Biotech Ltd reported a return on equity of 13.00%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.

CEO Mr. Sudhir Jairam Vaid
Employees 1,571
Listed 18 Aug 2023
Face Value ₹1
Shares Outstanding 20,92,32,408

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CONCORDBIO.md for Concord Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More